You are here

Article info

Article menu

Download PDFPDF

Uveitis
Original research
Adalimumab in patients with vision-threatening uveitis: real-world clinical experience

Authors

  • Timothy Lee Tang Lee Say Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaCardinal Santos Medical Center, San Juan, Manila, Philippines PubMed articlesGoogle scholar articles
  • Verlyn Yang Royal Hobart Hospital, Hobart, Tasmania, AustraliaGold Coast Hospital and Health Service, Southport, Queensland, AustraliaUniversity of Tasmania, Hobart, Tasmania, Australia PubMed articlesGoogle scholar articles
  • Jacob M Fingret Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Sophia Zagora Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaSaint Vincent's Hospital, Darlinghurst, New South Wales, AustraliaThe University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Richard Symes Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaThe University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Christine Younan Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaThe University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Elisa Eleanor Cornish Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaThe University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Nitin Verma Royal Hobart Hospital, Hobart, Tasmania, AustraliaUniversity of Tasmania, Hobart, Tasmania, AustraliaEast Timor Eye Program, Hobart, Tasmania, Australia PubMed articlesGoogle scholar articles
  • Anthony Sammel Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaUniversity of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Denis Wakefield Saint Vincent's Hospital, Darlinghurst, New South Wales, AustraliaUniversity of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Deborah Speden Royal Hobart Hospital, Hobart, Tasmania, Australia PubMed articlesGoogle scholar articles
  • Peter J McCluskey Sydney Hospital and Sydney Eye Hospital, Sydney, New South Wales, AustraliaRoyal Hobart Hospital, Hobart, Tasmania, AustraliaSaint Vincent's Hospital, Darlinghurst, New South Wales, AustraliaThe University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Peter J McCluskey; peter.mccluskey{at}sydney.edu.au
View Full Text

Citation

Tang Lee Say TL, Yang V, Fingret JM, et al
Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
BMJ Open Ophthalmology 2021;6:e000819. doi: 10.1136/bmjophth-2021-000819

Publication history

  • Received June 1, 2021
  • Accepted September 7, 2021
  • First published September 27, 2021.
Online issue publication 
September 27, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.